Abstract
Objective: To compare the lipoprotein (a) level in type II diabetics and non diabetics with acute coronary syndrome.
Materials and Methods: A total of 80 subjects including 40 patients with type II diabetes as cases and 40 non diabetics as control admitted in ICU matched for age and sex included in the study. Serum FBS, TG, cholesterol, LDL, HDL and serum Lp (a) in both the groups were measured. Statistical analysis was performed using SPSS software.
Results: Lp (a) level was significantly higher (p< 0.001) in diabetics as compared to control group.
Conclusion: Study concluded that increased serum Lp(a) concentration might be a risk factor in type II diabetic patients for coronary artery disease.
Keywords: Lipoprotein (a),type II diabetes,Acute coronary syndrome.
References
- Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595-607.
- De Fronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome respon-sible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14: 173-94.
- Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991; 34: 416-22.
- Morton NE, Berg-K, Dahlen G, Ferrell RE, Rhoads GG. Genetics of the Lp(a) lipoprotein in Japanese-Americans. Genet Epidemiol 1985;2: 113-2 1.
- Berg K, Dahlen G, Frick MH. Lp(a) lipoprotein and pre-i11-lipoprotein in patients with coronary heart disease. Clin Genet 1974;6:230-5.
- Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986;256: 2540-4.
- Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprstcin (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BM7 1990;301:1248-51.
- Utermann G: The mysteries of lipoprotein(a). Science1989; 246:904-910.
- Kronenberg F, Steinmetz A, kostner GM and Dieplinger H: Lipoprotein in health and disease. Crit Rev Clin Lab Sci 1996; 33:495- 543.
- Gurakar A, Hoeg JM, Kostner G et al. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985; 57:293-301.
- World Health Organisation: Diabetes Mellitus: Report of a WHO study group. Geneva, World Health Org,.1996(Tech Reo Ser No. 855).
- Bostem AG, Cupples LA, Srivastava LM. Lipoprotein (a): Biology and role in atherosclerotic vascular disease. Current Science 1999;76:1553-60.
- Kostner KM, Kostner GM. Lipoprotein(a): still an enigma? Curr Opin Lipidol. 2002; 13: 391-6.
- Mohan V, Deepa R, Harnath SP et al. Lipoprotein(a) is an independent risk factor for coronary artery disease in NIDDM patients in south India. Diabetes Care 1998;21:1819-23.
- Salehi R, Rahbani MN, Rashtchizadeh N. Lipoprotein(a), apo(a) phenotypes and dyslipidemia in acute coronary syndrome. Med J Islam Repub Iran 2001;14(4):139-143.
- Neki AD, Durrington PN, Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J. 1994;71:316-321.
- Ramirez LC,Arauz-Pacheco C,Lackner C, et al.Lipoprotein (a) levels in diabetes mellitus: relationship to metabolic control. Ann intern med 1992;117:42-7.
- Abu-Lebdeh HS, Hodge DO, Nguyen TT. Predictors of macrovascular disease in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2001; 76 (7): 707-12.
- Klaya F, Durlach V, Bertin E, Monier F, Monboisse JC, Gillery P. Evaluation of serum glycated lipoprotein(a) levels in non insulin-dependent diabetic patients. Clin Biochem. 1997; 30 (3): 227-30.
- Wieringa G. Lipoiprotein(a): what’s in a measure. Ann Clin Biochem. 2000; 37: 571-80.
Corresponding Author
Dr Amita Gupta
Address: 6, Nandgoan, Nandvihar, Near Girdhar nagar, Indore, M.P., 452001
Mobile No. 8109145378, 8223068877, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v6i4.117
